-DOCSTART- -X- O
Mucosal -X- _ O
vaccination -X- _ O
is -X- _ O
an -X- _ O
effective -X- _ O
strategy -X- _ O
for -X- _ O
generating -X- _ O
antigen-specific -X- _ O
immune -X- _ O
responses -X- _ O
against -X- _ O
mucosal -X- _ O
infections -X- _ O
of -X- _ O
foot-and-mouth -X- _ B-Patient
disease -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
FMDV -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
Lactobacillus -X- _ B-Intervention
plantarum -X- _ I-Intervention
strains -X- _ I-Intervention
NC8 -X- _ I-Intervention
and -X- _ I-Intervention
WCFS1 -X- _ I-Intervention
were -X- _ I-Intervention
used -X- _ I-Intervention
as -X- _ I-Intervention
oral -X- _ I-Intervention
delivery -X- _ I-Intervention
vehicles -X- _ I-Intervention
containing -X- _ I-Intervention
a -X- _ I-Intervention
pSIP411-VP1 -X- _ I-Intervention
recombinant -X- _ I-Intervention
plasmid -X- _ I-Intervention
to -X- _ O
initiate -X- _ B-Outcome
mucosal -X- _ I-Outcome
and -X- _ I-Outcome
systemic -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ O
guinea -X- _ B-Patient
pigs. -X- _ I-Patient
Guinea -X- _ B-Patient
pigs -X- _ I-Patient
were -X- _ O
orally -X- _ B-Intervention
vaccinated -X- _ I-Intervention
( -X- _ I-Intervention
three -X- _ I-Intervention
doses -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
NC8-pSIP411 -X- _ I-Intervention
, -X- _ I-Intervention
NC8-pSIP411-VP1 -X- _ I-Intervention
, -X- _ I-Intervention
WCFS1- -X- _ I-Intervention
pSIP411 -X- _ I-Intervention
, -X- _ I-Intervention
WCFS1-pSIP411-VP1 -X- _ I-Intervention
or -X- _ O
milk. -X- _ B-Comparison
Animals -X- _ B-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
NC8-pSIP411-VP1 -X- _ I-Outcome
and -X- _ I-Outcome
WCFS1- -X- _ I-Outcome
pSIP411-VP1 -X- _ I-Outcome
developed -X- _ I-Outcome
high -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
antigen-specific -X- _ I-Outcome
serum -X- _ I-Outcome
IgG -X- _ I-Outcome
, -X- _ I-Outcome
IgA -X- _ I-Outcome
, -X- _ I-Outcome
IgM -X- _ I-Outcome
, -X- _ I-Outcome
mucosal -X- _ I-Outcome
secretory -X- _ I-Outcome
IgA -X- _ I-Outcome
( -X- _ I-Outcome
sIgA -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
revealed -X- _ I-Outcome
stronger -X- _ I-Outcome
cell-mediated -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
enhanced -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
FMDV -X- _ I-Outcome
challenge -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
control -X- _ I-Outcome
groups. -X- _ I-Outcome
The -X- _ I-Outcome
recombinant -X- _ I-Outcome
pSIP411-VP1 -X- _ I-Outcome
effectively -X- _ I-Outcome
improved -X- _ I-Outcome
immunoprotection -X- _ I-Outcome
against -X- _ I-Outcome
FMDV -X- _ I-Outcome
in -X- _ I-Outcome
guinea -X- _ I-Outcome
pigs -X- _ I-Outcome
. -X- _ O

